Status:
COMPLETED
Diagnostic Validation of Rapid Detection of the COVID-19 Causative Virus (SARS-CoV-2) in Saliva Samples by Mass Spectrometry
Lead Sponsor:
Centre Hospitalier Universitaire de Nīmes
Collaborating Sponsors:
Technological Innovations for Detection and Diagnosis Laboratory
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Brief Summary
In order to control the COVID-19 pandemic, a policy for the diagnosis and screening of people likely to be infected with SARS-CoV-2 has been established The reference diagnostic test is RT-PCR on naso...
Eligibility Criteria
Inclusion
- The patient must not have opposed their inclusion in the study
- Patient presenting to the Walk-in Center for Emerging Biological Risks for SARS-CoV-2 screening by nasopharyngeal swab OR hospitalized in the Infectious and Tropical Diseases Department for severe SARS-CoV-2 infection, diagnosed by RT-PCR on nasopharyngeal sample, taken at Nîmes University Hospital, in the previous 24 hours.
Exclusion
- Patient already included in the study
- The subject is in a period of exclusion determined by a previous study
- It is impossible to give the subject clear information
- The patient is under safeguard of justice or state guardianship
- Patient unable to give consent
Key Trial Info
Start Date :
March 4 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 18 2023
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04712175
Start Date
March 4 2021
End Date
December 18 2023
Last Update
December 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Nîmes
Nîmes, France